Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 1/20 | 0.53 |
| ▸ | EIF2AK3 | Q9NZJ5 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | NEK7 | Q8TDX7 | 6/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6464384 | 0.90 | TEK (0.52) | TEKEIF2AK3MEN1NEK7RIPK2 | |
| SCHEMBL12934152 | 0.85 | NEK7 (0.53) | TEKEIF2AK3NEK7RIPK2 | |
| SCHEMBL6459716 | 0.84 | TEK (0.73) | TEKEIF2AK3MEN1NEK7RIPK2 | |
| SCHEMBL6459712 | 0.84 | TEK (0.73) | TEKEIF2AK3MEN1NEK7RIPK2 | |
| SCHEMBL6465140 | 0.84 | TEK (0.73) | TEKEIF2AK3MEN1NEK7RIPK2 | |
| SCHEMBL6463833 | 0.84 | TEK (0.56) | TEKEIF2AK3MEN1NEK7RIPK2 | |
| SCHEMBL6460593 | 0.83 | EIF2AK3 (0.58) | TEKEIF2AK3MEN1NEK7RIPK2 | |
| SCHEMBL12934107 | 0.81 | TEK (0.58) | TEKMEN1NEK7RIPK2 | |
| SCHEMBL6460259 | 0.81 | TEK (0.56) | TEKEIF2AK3MEN1NEK7RIPK2 | |
| SCHEMBL14183079 | 0.81 | TEK (0.72) | TEKEIF2AK3NEK7RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | claimed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | claimed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | TEK 1465/4885EIF2AK3 3756/4885MEN1 4582/4885 |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | TEK 22/4885EIF2AK3 928/4885MEN1 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.